Histone Deacetylases (HDACs) and Histone AcetylTransferases (HATs) have proven to be promising targets for drug intervention and there are a number of inhibitors currently being tested in both preclinical and clinical stages. New chemistries and screening tools continue to be developed to probe and modify the biology of these emerging drug targets. However, much remains to be elucidated about the functional significance of modulating these targets and understanding the signaling pathways that occur downstream. Cambridge Healthtech Institute’s inaugural conference on Targeting Histone Acetylation, tracks both the scientific and clinical progress being made to better understand the implications of targeting lysine acetylation in histones. The conference features interactive sessions and panel discussions geared to provide ample opportunity for active networking, brainstorming and collaborating.
Who should attend: Students, Postdoctoral fellows, Lab Technicians, Managers, Scientists, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Drug Discovery of epigenetic targets, Functional Screening, Compound Screening, Target ID and validation, Biomarker Discovery, Translational Research, and Clinicians working with drugs targeting histones.